Argenx Advances Efgartigimod Into China With Zai Lab Pact

Selects Option Of $75m In Stock For Upfront

Having just filed efgartigimod in the US, the European biotech has signed up Zai Lab to help develop and sell the potential autoimmune blockbuster in China, where an estimated 200,000 people live with myasthenia gravis.

Shanghai
200,000 people in China live with myasthenia gravis. • Source: Shutterstock

argenx N.V. has secured Zai Lab Ltd. as a partner in China for its closely watched pipeline-in-a-product efgartigimod, which has been touted as a future standard of care for the rare autoimmune disease myasthenia gravis (MG).

The Belgian-Dutch biotech has granted Zai Labs exclusive rights to develop and commercialize efgartigimod in mainland China, Hong Kong, Taiwan...

More from Deals

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By 

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.

BioNTech To Buy mRNA Rivals CureVac

 

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

More from Business